Annual report pursuant to Section 13 and 15(d)

Debt - Additional Information (Details)

v3.20.4
Debt - Additional Information (Details)
1 Months Ended 12 Months Ended
Nov. 02, 2020
USD ($)
$ / shares
shares
Sep. 08, 2020
USD ($)
Debtinstrument
$ / shares
shares
Apr. 30, 2020
USD ($)
Jan. 21, 2020
USD ($)
Debtinstrument
$ / shares
shares
Apr. 27, 2018
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Nov. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Debt Instrument [Line Items]                    
Accretion of debt discounts and deferred financing costs               $ 10,929,000 $ 362,000 $ 360,000
Fair value of derivative liability       $ 27,038,000            
Fair value of derivative liability related to rights offering       82,000            
Financing transaction costs               $ 2,848,000    
Ordinary Shares                    
Debt Instrument [Line Items]                    
Number of warrants to purchase ordinary shares | shares         19,890 19,890   19,890    
Loan and Security Agreement | Silicon Valley Bank (SVB)                    
Debt Instrument [Line Items]                    
Loan and security agreement entered date               Apr. 27, 2018    
Funded amount under agreement         $ 15,000,000          
Remaining borrowing facility available date         Oct. 31, 2019          
Maximum amount available under agreement         $ 30,000,000          
Non-utilization fee percentage of undrawn principal amount         1.50%          
Frequency of amortization payments               monthly    
Date of first required payment of initial draw         Nov. 01, 2019          
Minimum fixed interest rate per annum         8.31%          
Final interest rate payment on outstanding principal         4.20%          
Principal and interest payment, maturity date         Mar. 01, 2022          
Final payment fee         $ 630,000          
Prepayment fee in first year         4.00%          
Prepayment fee in second year         3.00%          
Prepayment fee thereafter         2.00%          
Principal payment during the period         $ 6,207,000          
Effective annual interest rate on outstanding debt           12.51%   12.51%    
Interest expense               $ 1,355,000 1,761,000  
Accretion of debt discounts and deferred financing costs               $ 404,000 $ 362,000  
Loan and Security Agreement | Silicon Valley Bank (SVB) | Wall Street Journal Prime Rate                    
Debt Instrument [Line Items]                    
Basis spread on interest rate         3.89%          
Loan and Security Agreement | Silicon Valley Bank (SVB) | Maximum                    
Debt Instrument [Line Items]                    
Maximum amount available under second draw         $ 15,000,000          
Silicon Valley Bank and Life Sciences Fund II LLC                    
Debt Instrument [Line Items]                    
Percentage of purchase additional ordinary shares equal to term loan divided by applicable exercise price         2.50%          
Silicon Valley Bank and Life Sciences Fund II LLC | Series B Convertible Preferred Shares                    
Debt Instrument [Line Items]                    
Number of warrants to purchase ordinary shares | shares         19,890 19,890   19,890    
Warrants to purchase ordinary shares, exercise price | $ / shares         $ 18.85 $ 18.85   $ 18.85    
2025 Exchangeable Notes                    
Debt Instrument [Line Items]                    
Interest expense               $ 3,180,000    
Accretion of debt discounts and deferred financing costs               7,764,000    
Aggregate principal amount           $ 9,891,000   $ 9,891,000    
Debt instrument, payment terms               The Company will be required to pay the holders of the Exchangeable Notes the greater of three times the outstanding principal amount of such Exchangeable Notes and the consideration that would be received by the holders of such Exchangeable Notes in connection with such Fundamental Change if the holders had exchanged their notes for ordinary shares immediately prior to the consummation of such Fundamental Change, plus any accrued and unpaid interest.    
Financing transaction costs               $ 2,848,000    
Financing transaction costs, capitalized       2,814,000            
2025 Exchangeable Notes | Private Placement                    
Debt Instrument [Line Items]                    
Aggregate principal amount   $ 200,000   $ 51,600,000            
Debt instrument interest rate   6.50%   6.50%            
Debt instrument price per unit   $ 1,000   $ 1,000            
Fair value of derivative liability       27,038,000            
2025 Exchangeable Notes | Rights Offering                    
Debt Instrument [Line Items]                    
Fair value of derivative liability related to rights offering   82,000                
RLNs | Private Placement                    
Debt Instrument [Line Items]                    
Aggregate principal amount   $ 20,000   $ 100,000            
Number of debt instruments within each notes | Debtinstrument   50   50            
Securities | Private Placement                    
Debt Instrument [Line Items]                    
Debt instrument price per unit   $ 1,000   $ 1,000            
Debt instrument, shares embedded within each unit, shares | shares 1,286.1845 1,000   1,000            
Debt instrument, shares embedded within each unit, value $ 1,000 $ 1,000   $ 1,000            
Debt instrument, shares embedded within each unit, exchange price | $ / shares $ 0.7775 $ 1.00   $ 1.00            
Paycheck Protection Program | Silicon Valley Bank (SVB) | Iterum Therapeutics US Limited                    
Debt Instrument [Line Items]                    
Interest expense     $ 1,000              
Aggregate principal amount     $ 744,000              
Debt instrument interest rate     1.00%              
Debt instrument maturity period     2 years              
Debt instrument, description     Under the terms of the agreement, there shall be no payments due by the Company until the SBA remits the forgiveness amount to the borrower or 10 months after the end of the six-month period beginning April 30, 2020 (the Deferral Period). Following the Deferral Period, equal monthly repayments of principal and interest will be due to fully amortize the principal amount outstanding on the PPP loan by the maturity date         Under the terms of the agreement, there shall be no payments due by the Company until after the Deferral Period. Following the Deferral Period, equal monthly repayments of principal and interest will be due to fully amortize the principal amount outstanding on the PPP loan by the maturity date.    
Debt instrument, forgiveness loan             $ 340,000      
Debt instrument, remaining amount amortized           404,000   $ 404,000    
Debt Instrument, equal monthly repayments           $ 26,000   $ 26,000